|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
12 December 2020 |
|
Main ID: |
NCT02284633 |
|
Date of registration:
|
04/11/2014 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
|
|
Scientific title:
|
Use of a New Blood Test to Identify Response to Targeted Treatment in Patients With EGFR Mutated Lung Cancer. Evaluation in a Multicenter Study |
|
Date of first enrolment:
|
September 2014 |
|
Target sample size:
|
250 |
|
Recruitment status: |
Active, not recruiting |
|
URL:
|
https://clinicaltrials.gov/show/NCT02284633 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Denmark
| | | | | | | |
|
Contacts
|
|
Name:
|
Eva Hansen, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Aarhus University Hospital |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Lung cancer with a biopsy verified EGFR mutation eligible for treatment with erlotinib
Exclusion Criteria:
- None
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
|
Health Condition(s) or Problem(s) studied
|
|
Lung Neoplasms
|
|
Primary Outcome(s)
|
|
Progression Free Survival
[Time Frame: 2 years]
|
|
Secondary ID(s)
|
|
1-16-02-431-14
|
|
1-10-72-83-14
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|